Copyright
©The Author(s) 2024.
World J Stem Cells. Dec 26, 2024; 16(12): 1012-1021
Published online Dec 26, 2024. doi: 10.4252/wjsc.v16.i12.1012
Published online Dec 26, 2024. doi: 10.4252/wjsc.v16.i12.1012
Table 2 Information about cell product
| Cell product | Case 1 | Case 2 | Case 3 | Case 4 | |||||
| 1st | 2nd | 1st | 2nd | 1st | 2nd | 1st | 2nd | ||
| Apheresis product | Total MNC number (× 1010) | 6.3 | 5.5 | 14.5 | 11 | 11.7 | 8.9 | 13.7 | 16.9 |
| CD34+ cell number (× 107) | 9.5 | 10.9 | 6.1 | 6.4 | 43.3 | 32.6 | 23.5 | 19.9 | |
| Cell product after magnetic sorting | CD34+ cell number (× 107) | 5.5 | 7.6 | 1.3 | 0.9 | 27.3 | 22.4 | 8.9 | 2.5 |
| Viability (%) | 97.3 | 98.5 | 96.9 | 97.2 | 97.9 | 98.3 | 98.2 | 96.4 | |
| CD34+ cell purity (%) | 52.7 | 60.7 | 84.6 | 89.2 | 94.6 | 81.6 | 86.7 | 93.0 | |
| Administered cell number (× 107) | 4.0 | 4.0 | 1.3 | 0.9 | 5.2 | 5.2 | 7.3 | 2.5 | |
- Citation: Ohtake T, Sato T, Tsukiyama T, Muraoka S, Mitomo A, Maruyama H, Yamano M, Mochida Y, Ishioka K, Oka M, Moriya H, Hidaka S, Masuda H, Asahara T, Kobayashi S. Preliminary evidence of renal function improvement in chronic progressive kidney disease using autologous CD34+ cell therapy: A clinical trial. World J Stem Cells 2024; 16(12): 1012-1021
- URL: https://www.wjgnet.com/1948-0210/full/v16/i12/1012.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v16.i12.1012